Clinical characteristics and follow-up of Korean patients with adrenal incidentalomas

Korean Journal of Internal Medicine

Volumn 28, Issue 5, 2013, Pages 557-564

  Cho, Yoon Young ^a   Suh, Sunghwan ^a   Joung, Ji Young ^a   Jeong, Hyemin ^a   Je, Dongmo ^a   Yoo, Hongseok ^a   Park, Taek Kyu ^a   Min, Yong Ki ^a   Kim, Kwang Won ^a   Kim, Jae Hyeon ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Adrenal gland neoplasms; Aldosterone; Cushing syndrome; Pheochromocytoma

Indexed keywords

ALDOSTERONE; DEXAMETHASONE; HYDROCORTISONE; METADRENALIN; NORMETADRENALIN; RENIN; VANILMANDELIC ACID; HORMONE; TUMOR MARKER;

ADRENAL CANCER; ADRENAL INCIDENTALOMA; ADRENAL METASTASIS; ADRENALECTOMY; ADULT; ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CUSHING SYNDROME; DEXAMETHASONE SUPPRESSION TEST; FEMALE; FOLLOW UP; GENDER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HORMONE DETERMINATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; PHEOCHROMOCYTOMA; PRIMARY HYPERALDOSTERONISM; RADIOIMMUNOASSAY; RETROSPECTIVE STUDY; RISK FACTOR; SOUTH KOREA; TERTIARY HEALTH CARE; ADRENAL GLAND NEOPLASMS; AGED; BLOOD; DISEASE COURSE; HYPERALDOSTERONISM; MIDDLE AGED; PREDICTIVE VALUE; PROGNOSIS; RISK; STATISTICAL MODEL; TERTIARY CARE CENTER; TIME;

ADRENAL GLAND NEOPLASMS; AGED; CUSHING SYNDROME; DISEASE PROGRESSION; FEMALE; HORMONES; HUMANS; HYPERALDOSTERONISM; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PHEOCHROMOCYTOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; TERTIARY CARE CENTERS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 84883770969     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2013.28.5.557     Document Type: Article

References (35)

1. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 2004;25:309-340.
2. Bovio S, Cataldi A, Reimondo G, et al. Prevalence of ad-renal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest 2006;29:298-302.
3. Grumbach MM, Biller BM, Braunstein GD, et al. Man-agement of the clinically inapparent adrenal mass (in-cidentaloma). Ann Intern Med 2003;138:424-429.
4. Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prev-alence and natural history of adrenal incidentalomas. Eur J Endocrinol 2003;149:273-285.
5. Mantero F, Terzolo M, Arnaldi G, et al. A survey on ad-renal incidentaloma in Italy: Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000;85:637-644.
6. Allolio B, Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006;91:2027-2037.
7. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phae-ochromocytoma. Lancet 2005;366:665-675.
8. Prinz RA, Brooks MH, Churchill R, et al. Incidental asymptomatic adrenal masses detected by computed tomographic scanning: is operation required? JAMA 1982;248:701-704.
9. Geelhoed GW, Druy EM. Management of the adrenal incidentaloma. Surgery 1982;92:866-874.
10. Ng VW, Ma RC, So WY, et al. Evaluation of functional and malignant adrenal incidentalomas. Arch Intern Med 2010;170:2017-2020. 2005;20:303-309.
11. Jeong HS, Kim HJ, Kim HS, et al. Clinical characteristics for 132 patients with adrenal incidentaloma. J Korean Endocr Soc 2007;22:260-265.
12. Murai M, Baba S, Nakashima J, Tachibana M. Management of incidentally discovered adrenal masses. World J Urol 1999;17:9-14.
13. Kim HY, Kim SG, Lee KW, et al. Clinical study of adrenal incidentaloma in Korea. Korean J Intern Med 2005;20:303-309.
14. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. Endocr Rev 1995;16:460-484.
15. Yeh HC. Sonography of the adrenal glands: nor-mal glands and small masses. AJR Am J Roentgenol 1980;135:1167-1177.
16. Barzon L, Scaroni C, Sonino N, et al. Incidentally dis-covered adrenal tumors: endocrine and scintigraphic correlates. J Clin Endocrinol Metab 1998;83:55-62.
17. Flecchia D, Mazza E, Carlini M, et al. Reduced serum levels of dehydroepiandrosterone sulphate in adrenal incidentalomas: a marker of adrenocortical tumour. Clin Endocrinol (Oxf) 1995;42:129-134.
18. Herrera MF, Grant CS, van Heerden JA, Sheedy PF, Il-strup DM. Incidentally discovered adrenal tumors: an institutional perspective. Surgery 1991;110:1014-1021.
19. Abecassis M, McLoughlin MJ, Langer B, Kudlow JE. Serendipitous adrenal masses: prevalence, significance, and management. Am J Surg 1985;149:783-788.
20. Barzon L, Fallo F, Sonino N, Boscaro M. Development of overt Cushing's syndrome in patients with adrenal incidentaloma. Eur J Endocrinol 2002;146:61-66.
21. Bulow B, Ahren B; Swedish Research Council Study Group of Endocrine Abdominal Tumours. Adrenal in-cidentaloma: experience of a standardized diagnostic programme in the Swedish prospective study. J Intern Med 2002;252:239-246.
22. Kasperlik-Zeluska AA, Roslonowska E, Slowinska-Srzed-nicka J, et al. Incidentally discovered adrenal mass (incidentaloma): investigation and management of 208 patients. Clin Endocrinol (Oxf) 1997;46:29-37.
23. Russell RP, Masi AT, Richter ED. Adrenal cortical ade-nomas and hypertension: a clinical pathologic analysis of 690 cases with matched controls and a review of the literature. Medicine (Baltimore) 1972;51:211-225.
24. Comlekci A, Yener S, Ertilav S, et al. Adrenal inciden-taloma, clinical, metabolic, follow-up aspects: single centre experience. Endocrine 2010;37:40-46.
25. Barzon L, Scaroni C, Sonino N, Fallo F, Paoletta A, Bos-caro M. Risk factors and long-term follow-up of adrenal incidentalomas. J Clin Endocrinol Metab 1999;84:520-526.
26. Hamrahian AH, Ioachimescu AG, Remer EM, et al. Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab 2005;90:871-877.
27. Korobkin M, Brodeur FJ, Yutzy GG, et al. Differentia-tion of adrenal adenomas from nonadenomas using CT attenuation values. AJR Am J Roentgenol 1996;166:531-536.
28. Cirillo RL Jr, Bennett WF, Vitellas KM, Poulos AG, Bova JG. Pathology of the adrenal gland: imaging features. AJR Am J Roentgenol 1998;170:429-435.
29. Terzolo M, Bovio S, Pia A, et al. Midnight serum cor-tisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. Eur J Endocrinol 2005;153:307-315.
30. Tauchmanova L, Rossi R, Biondi B, et al. Patients with subclinical Cushing's syndrome due to adrenal adeno-ma have increased cardiovascular risk. J Clin Endocri-nol Metab 2002;87:4872-4878.
31. Rossi R, Tauchmanova L, Luciano A, et al. Subclinical Cushing's syndrome in patients with adrenal inciden-taloma: clinical and biochemical features. J Clin Endo-crinol Metab 2000;85:1440-1448.
32. Libe R, Dall'Asta C, Barbetta L, Baccarelli A, Beck-Pec-coz P, Ambrosi B. Long-term follow-up study of pa-tients with adrenal incidentalomas. Eur J Endocrinol 2002;147:489-494.
33. Song JH, Chaudhry FS, Mayo-Smith WW. The inci-dental indeterminate adrenal mass on CT (> 10 H) in patients without cancer: is further imaging necessary? Follow-up of 321 consecutive indeterminate adrenal masses. AJR Am J Roentgenol 2007;189:1119-1123.
34. Young WF Jr. Clinical practice: the incidentally discov-ered adrenal mass. N Engl J Med 2007;356:601-610.
35. Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S. Recom-mended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant: time for a rethink? Eur J Endo-crinol 2009;161:513-527.